Nevertheless, these and other studies confirm that the modulation of the expression levels of TRAIL-R1 and TRAIL-R2 achieved by several agents, including ionizing radiation, chemotherapy and histone deacetylase inhibitors, may provide a valuable approach to develop combined therapies to enhance the sensitivity of HCC cells to TRAIL induced apoptosis (reviewed in [29]). Here, TNFRSF10B is linked to hepatocellular carcinoma.